title: Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
abstract: OBJECTIVE
  Phase I study to determine the maximum tolerated dose (MTD) of fluorouracil (FU) in the docetaxel/cisplatin/FU (TPF) regimen when combined with cetuximab (C) for induction treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN).
  
  
  METHODS
  Patients with previously untreated SCCHN were enrolled. FU cohorts were 700, 850, and 1,000 mg/m(2)/d for 4 days via continuous infusion. TPF given every 3 weeks for three cycles and C was given weekly for a total of 9 weeks, starting on day 1 of TPF. All patients received chemoradiotherapy after C-TPF.
  
  
  RESULTS
  A total of 30 patients were enrolled and 28 were assessable. The median age was 57 years, 92% had stage 4 disease, 71% were oropharynx, and 100% had a performance status of 0. No dose-limiting toxicity (DLT) was encountered on dose levels 1 and 2. At dose level 3 of 1000 mg/m(2), one DLT was encountered and three more patients were enrolled with no DLTs. In the expansion cohort at the MTD, three DLT's were encountered. The decision was made to decrease the FU from 1,000 mg/m(2) to dose level 2 of 850 mg/m(2). A total of 13 patients were enrolled at the MTD of 850 mg/m(2). The number of average weeks that C was delivered was seven of nine planned.
  
  
  CONCLUSIONS
  C-TPF appears to be safe and feasible as given in this study. GI toxicity (mucositis, enteritis, and diarrhea) appears to be the major combined DLT. Reducing the FU in TPF to 850 mg/m(2) reduces GI toxicity and is the recommended phase II dose.
authors.affiliation: Dana-Farber Cancer Institute, 44 Binney St, Boston, MA02115, USA. robert_haddad@dfci.harvard.edu
authors.forename: Robert I
authors.initials: RI
authors.lastname: Haddad
authors.forename: Roy B
authors.initials: RB
authors.lastname: Tishler
authors.forename: Charles
authors.initials: C
authors.lastname: Norris
authors.forename: Laura
authors.initials: L
authors.lastname: Goguen
authors.forename: Tracy A
authors.initials: TA
authors.lastname: Balboni
authors.forename: Rosemary
authors.initials: R
authors.lastname: Costello
authors.forename: Lori
authors.initials: L
authors.lastname: Wirth
authors.forename: Jochen
authors.initials: J
authors.lastname: Lorch
authors.forename: Britta
authors.initials: B
authors.lastname: Andreozzi
authors.forename: Donald
authors.initials: D
authors.lastname: Annino
authors.forename: Marshall R
authors.initials: MR
authors.lastname: Posner
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D000068818:Cetuximab; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009367:Neoplasm Staging; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D000077143:Docetaxel; D000068818:Cetuximab; D002945:Cisplatin; D005472:Fluorouracil